Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants

Oncol Res. 1994;6(2):71-7.


Multidrug resistance in human cancer is associated with overexpression of the MDR1 gene, which encodes a plasma membrane energy-dependent efflux pump termed P-glycoprotein (or the multidrug transporter), which confers cross-resistance to multiple hydrophobic natural product cytotoxic drugs. We have previously shown in cotransfection experiments that activity of the human MDR1 gene promoter is modulated by Ras and p53, suggesting that expression of the MDR1 gene may be associated with the activation of oncogenes and/or functional loss of tumor suppressor genes during oncogenesis. To further characterize the effects of p53 on the MDR1 promoter, we have shown in the current study that the region of the promoter that is required for transactivation by p53 mutants overlaps with the region that is essential for basal promoter activity. In addition, we also have shown that several different p53 mutants transactivate the MDR1 promoter in several different cell types, including embryo fibroblasts derived from the p53-deficient (p53-l-) mice generated by gene targeting.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cells, Cultured
  • Chick Embryo
  • Drug Resistance, Multiple / genetics*
  • Fibroblasts / physiology
  • Gene Expression Regulation, Neoplastic*
  • Genes, p53*
  • Genes, ras
  • Humans
  • Mutation*
  • Promoter Regions, Genetic*
  • Transcriptional Activation*
  • Transfection
  • Tumor Suppressor Protein p53 / pharmacology
  • Tumor Suppressor Protein p53 / physiology


  • Tumor Suppressor Protein p53